Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06731959
PHASE2

A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD

Sponsor: Aer Therapeutics

View on ClinicalTrials.gov

Summary

AER-01-002 is a Phase 2a study being conducted to determine if inhaled fexlamose is an effective and safe treatment for adults with moderate to severe COPD. Study will compare active drug to placebo.

Official title: A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose (AER-01) Inhalation Solution in the Treatment of Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease

Key Details

Gender

All

Age Range

40 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2024-12

Completion Date

2026-01

Last Updated

2024-12-13

Healthy Volunteers

No

Conditions

Interventions

DRUG

Flexlamose

Fexlamose solution via nebulizer for 28 days

DRUG

Placebo

Placebo solution via nebulizer for 28 days